Key Points
- Brent Sabatini, Vir's CAO, sold 1,530 shares on Feb. 13 at an average price of $7.79 for $11,918.70, leaving him with 47,872 shares (a 3.10% reduction), according to an SEC filing.
- Analyst coverage is skewed positive with seven Buys and one Sell, a consensus of "Moderate Buy" and an average price target of $16.29 (individual targets range roughly $14–$26).
- Hedge funds have been increasing exposure (e.g., Virtus +82.4%, Corient +1%) and new stakes from Tudor, Polymer and Quadrature were reported, with institutional investors owning 65.32% of the company.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,530 shares of the stock in a transaction on Friday, February 13th. The stock was sold at an average price of $7.79, for a total value of $11,918.70. Following the transaction, the chief accounting officer directly owned 47,872 shares in the company, valued at approximately $372,922.88. This represents a 3.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Vir Biotechnology Stock Up 4.4%
Shares of NASDAQ:VIR opened at $7.83 on Thursday. The company has a market cap of $1.09 billion, a P/E ratio of -2.17 and a beta of 1.69. The business has a fifty day simple moving average of $6.69 and a 200-day simple moving average of $5.89. Vir Biotechnology, Inc. has a 52 week low of $4.16 and a 52 week high of $9.97.
Hedge Funds Weigh In On Vir Biotechnology
Hedge funds have recently made changes to their positions in the business. Corient Private Wealth LLC boosted its position in Vir Biotechnology by 1.0% during the 4th quarter. Corient Private Wealth LLC now owns 262,211 shares of the company's stock worth $1,572,000 after purchasing an additional 2,515 shares during the period. Virtus Investment Advisers LLC raised its position in Vir Biotechnology by 82.4% in the fourth quarter. Virtus Investment Advisers LLC now owns 39,764 shares of the company's stock valued at $240,000 after purchasing an additional 17,966 shares during the period. Tudor Investment Corp ET AL acquired a new position in shares of Vir Biotechnology during the fourth quarter worth about $414,000. Polymer Capital Management US LLC acquired a new position in shares of Vir Biotechnology during the fourth quarter worth about $202,000. Finally, Quadrature Capital Ltd purchased a new stake in shares of Vir Biotechnology in the fourth quarter worth about $300,000. Hedge funds and other institutional investors own 65.32% of the company's stock.
Analyst Ratings Changes
VIR has been the topic of several research analyst reports. HC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Vir Biotechnology in a research report on Tuesday, December 30th. Needham & Company LLC reiterated a "buy" rating and issued a $14.00 price target on shares of Vir Biotechnology in a report on Monday, February 9th. Barclays set a $26.00 price objective on Vir Biotechnology in a report on Tuesday. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Vir Biotechnology in a report on Monday, December 22nd. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Vir Biotechnology presently has an average rating of "Moderate Buy" and an average price target of $16.29.
View Our Latest Analysis on VIR
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
